Senior Vice President, Research & Development, ModMab Therapeutics, Inc.
BIOGRAPHY
FEB 27, 2019 3:00 PM PST
Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates
Presented at:
Drug Discovery Virtual Event Series 2019
Speaker
Abstract
In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies available. (There are currently 23 ADCs in total being studied in 45 combination trials with 10 different immune checkpoint modulators).
Learning Objectives:
1. This presentation will discuss past, present challenges associated with developing antibody-drug conjugates (ADCs), a novel modality of targeted cancer chemotherapy
2. Presentation will also highlight key factors that influence in developing next generation ADCs.
You May Also Like
MAY 29, 2024 | 8:00 AM
A-TEEM spectroscopy is an emerging technique with huge potential for QC laboratories in the pharmaceutical and biopharmaceutical industries. We present a set of tools for A-TEEM spectroscopy...
MAY 29, 2024 | 9:00 AM
C.E. CREDITS
Histology laboratorians in the research world move fast, but those who perform cryosectioning know that these particular tissues require lighting speed and precision. Cryosectioning is the a...
MAY 15, 2024 | 10:00 AM
Join this year's poster presenters in the Poster Hall during the Poster Networking Hour, Wednesday, September 6th, from 1:00 –2:00 PM PDT , to chat live about their posters and lat...
JUN 19, 2024 | 8:30 AM
Join us for an illuminating webinar as we delve into the realm of open automation with Inpeco, the global leader in Total Laboratory Automation. Discover how their groundbreaking s...
FEB 27, 2019 3:00 PM PST
Share
Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates
Presented at:
Drug Discovery Virtual Event Series 2019
Loading Comments...